What is ALNY's P/E ratio?

ALNYLAM PHARMACEUTICALS INC (ALNY) currently trades at a P/E ratio of 42.63.

ALNYLAM PHARMACEUTICALS INC reports a Return on Equity (ROE) of 53.68%.

What is ALNY's dividend yield?

ALNYLAM PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is ALNY's Quality Score?

Our AI rates ALNY's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ALNY?

Our AI Timing Score for ALNY is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ALNY belong to?

ALNYLAM PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ALNY (NASDAQ) Stock Analysis | ALNYLAM PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ALNY AI Analysis Summary

Our AI summary for ALNY: ALNYLAM PHARMACEUTICALS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 42.63, ROE of 53.68%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ALNY

ALNYLAM PHARMACEUTICALS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 205.52

0.04 (0.02%) Day Change

Watchlist Portfolio Compare Chart

42.63

P/E

0.98

D/E

53.7%

ROE

11.3%

ROA

0.00%

Div Yield

-0.42

PEG

ALNYLAM PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 205.52 Price 0.04 (0.02%) Day Change	NEWS SCORE: 95

ALNY, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

52%

In Recommendations?	In "Invest - GROWTH" Section
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	2046
Magic Formula Rank by ROE	2046
Magic Formula Rank by ROIC	1256
Price	205.52
PBV / Sector	25.51 / 5.20
Earning Per Share	4.32

PE / Sector	42.63 / 19.97
PEG or PE/Growth / Sector	-0.42 / 1.22
Average 1M Daily Value	558.42 M
Average 1W Daily Value	816.08 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	13.46 / 98.71
NPM Average (%) / Sector	-24.72 / -1,721.76
NPM Change Average (%) / Sector	-58.86 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	11.25 / 27.02
ROA Average (%) / Sector	-6.48 / -368.17
ROA Change Average (%) / Sector	-56.27 / 5,404.12
ROE (%) / Sector	53.68 / 3.47 GREAT
ROE Average (%) / Sector	118.65 / 6.51 GREAT
ROE Change Average (%) / Sector	-113.62 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:27
Symbol	ALNY
Name	ALNYLAM PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	133.51 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	27,434.16 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Phone: 617 551 8200

Website: https://www.alnylam.com

Employees: 2,500

Sector: Healthcare >> Biotechnology

Description: Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.